Abstract
The advent of BCR-ABL1 tyrosine kinase inhibitors has revolutionized the treatment and prognosis of chronic myeloid leukemia. Life expectancy for pati......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
